Sugganth Daniel Pillei MD Illumina

Summary

• Sugganth Daniel facilitates cross-functional team interactions between product/franchise, clinical lab, R&D, pharma BD and commercial and marketing teams, he supports US & international medical affairs teams to further clinical studies with academic and industry collaborations, regulatory review and content creation.
  
  He is American Board of Pathology (ABP) board-certified and residency and fellowship trained in Anatomic, Clinical and Cyto-Pathology at Columbia University NY and at the University of Michigan, Ann Arbor and ABP and American Board of Medical Genetics and Genomics (ABMGG) board-certified and fellowship-trained in Molecular & Genetic Pathology at the Baylor College of Medicine and MD Anderson Cancer Center, Houston. He completed a clinical pathology residency in India in 2004 and worked as a pathology and blood bank director in Chennai. He previously held academic appointment as pathology faculty with the George Washington University, medical directorship with Foundation Medicine and most recently served as Medical Director of the Molecular Oncology and Genetics labs for Quest Diagnostics. He serves on committees with the CLSI, CLIA and ACLA.
  
  Areas of Expertise: Molecular Oncology, Genetics and Anatomic/Clinical Pathology with expertise in assay development and optimization in clinical diagnostics. Experienced in Pathology and Genomics, and in Lab Information System adaptations and in utilization of digital pathology, for histopathology, IHC, and FISH imaging within clinical testing environments. Familiar with CLIA/CMS, CAP, CLSI, NYS, and FDA-QSR requirements for clinical labs and with professional society recommendations for clinical diagnostic assay usage and performance monitoring.
  
  Certifications and Licenses: ABP/ABMGG Board-certified in Anatomic, Clinical, and Molecular Pathology. Licenses held: NYS-DOH (Oncology and Cellular Markers) Lab Director CoQ and Medical (Physician and Surgeon) License; Medical Board of California